If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIdox Group Regulatory News (IDOX)

  • There is currently no data for IDOX

Rule 19.6(b) update

26 May 2026 13:45

RNS Number : 6559F
Long Path Partners LP
26 May 2026
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULES 19.6(B) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE")

FOR IMMEDIATE RELEASE

26 MAY 2026

Frankel UK Bidco Limited

(a newly-formed company indirectly owned by Long Path Co-Investment Fund #6, LP (acting by its general partner, Long Path Co-Investment Fund #6 GP, LLC), Long Path Smaller Companies Fund, LP (acting by its general partner Long Path Fund GP, LLC), Long Path Smaller Companies Master Fund, Ltd. and Long Path Opportunities Fund II, LP (acting by its general partner, Long Path Opportunities Fund GP, LLC))

Director Resignation and Rule 19.6(b) update in relation to the recommended acquisition of Idox Plc ("Idox")

Frankel UK Bidco Limited ("Frankel") refers to the recommended cash offer for the entire issued and to be issued ordinary share capital of Idox, which was implemented by means of a takeover offer as defined in Chapter 3 of Part 28 of the Companies Act 2006 (the "Acquisition"). The offer document in respect of the Offer was published and posted to Idox Shareholders on 15 January 2026 (the "Offer Document") and the Offer was declared unconditional on 21 April 2026.

Capitalised terms used but not defined in this announcement have the meanings given to them in the Offer Document.

CEO retirement

Frankel and Idox announce that David Meaden has informed the board of Idox that, following the successful completion of the Offer, he has decided to retire from his executive career after leading Idox through this important period. David will step down as Chief Executive Officer and resign as a director of Idox on 29 May 2026, being the date of the proposed cancellation of the admission to trading of Idox Shares on AIM in accordance with Rule 41 of the AIM Rules for Companies.

David will continue to lead the business until that date and will support an orderly transition to Jonathan Legdon, Idox's current Chief Operating Officer, who is expected to succeed David as Chief Executive Officer.

This announcement is made pursuant to Rule 19.6(b) of the Code and constitutes an update to the statements of intention made by Frankel in the Offer Document in respect of the board and management of Idox following completion of the Offer. Frankel continues to recognise the importance of Idox's management team and looks forward to partnering with Idox's continuing management team. Save as set out in this announcement, Frankel's stated intentions in respect of the board and management of Idox remain unchanged.

David Meaden, Chief Executive Officer, said:

"I would like to thank the shareholders, staff, and the Board for their insight and support during my time as CEO at Idox. I believe we have built an excellent company, and with Jonathan's leadership and Long Path's support, the business will continue to thrive."

Jonathan Legdon, Chief Operating Officer, said:

"Dave has made a significant contribution to Idox over many years and has led the business with commitment, clarity and a strong sense of purpose. We are grateful for the foundations he has helped build. As we look ahead, we do so with confidence, supported by Long Path, who have been a long-term investor and understand both the strength of the business and the opportunities in front of us."

Enquiries

Frankel and Long Path

Will Brennan

Brian Nelson

John Cresson

Kyle Warren

via Canaccord Genuity

Idox

Chris Stone, Non-Executive Chair

David Meaden, Chief Executive Officer

Anoop Kang, Chief Financial Officer

+44 (0) 333 011 1200

Peel Hunt LLP (Nominated Adviser and Corporate Broker to Idox)

Neil Patel

Benjamin Cryer

Kate Bannatyne

Alice Lane

+44 (0)20 7418 8900

MHP (PR Adviser to Idox)

Reg Hoare

Ollie Hoare

Finn Taylor

idox@mhpgroup.com

+ 44 (0) 7831 406 117

Kirkland & Ellis International LLP is acting as legal adviser to Frankel and Long Path.

Pinsent Masons LLP is acting as legal adviser to Idox.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
OUPPPURCAUPQPUA
Date   Source Headline
27th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 20237:00 amRNSYear End Trading Update
9th Nov 202310:25 amRNSHolding(s) in Company
6th Nov 20233:01 pmRNSHolding(s) in Company
2nd Nov 20232:10 pmRNSHolding(s) in Company
2nd Nov 202310:09 amRNSHolding(s) in Company
1st Nov 202311:48 amRNSHolding(s) in Company
18th Oct 20237:00 amRNSAdoption of New LTIP and Grant of Options
4th Oct 20237:00 amRNSExercise of Share Options & Total Voting Rights
25th Sep 202310:06 amRNSHolding(s) in Company
11th Sep 20237:00 amRNSExercise of Share Options & Total Voting Rights
31st Aug 20237:00 amRNSExercise of Share Options & Total Voting Rights
21st Aug 20237:00 amRNSAcquisition
4th Aug 20237:00 amRNSExercise of Share Options & Total Voting Rights
3rd Aug 20231:49 pmRNSHolding(s) in Company
1st Aug 20237:00 amRNSChange of Registered Address
14th Jul 20237:00 amRNSExercise of Share Options & Total Voting Rights
27th Jun 20237:00 amRNSExercise of Share Options & Total Voting Rights
13th Jun 20237:00 amRNSPayment of Earnout and Allotment of Shares
12th Jun 20234:44 pmRNSHolding(s) in Company
8th Jun 20237:00 amRNSHalf Year results
18th May 20237:00 amRNSHalf Year 2023 Trading Update
23rd Mar 20232:33 pmRNSResult of AGM
23rd Mar 20237:00 amRNSAGM Trading Update
3rd Mar 20237:00 amRNSPosting of Annual Report and Notice of AGM
15th Feb 20237:00 amRNSExercise of Share Options & Total Voting Rights
9th Feb 202311:03 amRNSHolding(s) in Company
3rd Feb 20237:00 amRNSExercise of Share Options & Total Voting Rights
26th Jan 20237:00 amRNSFinal Results
11th Jan 20237:00 amRNSNotice of Final Results
15th Dec 20227:00 amRNSPayment of Earnout and Allotment of Shares
8th Dec 20221:17 pmRNSHolding(s) in Company
16th Nov 20227:00 amRNSTrading Statement
14th Nov 20227:00 amRNSHolding(s) in Company
7th Oct 20222:42 pmRNSHolding(s) in Company
3rd Oct 20227:00 amRNSAcquisition
26th Sep 20227:00 amRNSExercise of Share Options & Total Voting Rights
1st Aug 20227:00 amRNSTotal Voting Rights
15th Jul 20227:00 amRNSIdox awarded new contract for Idox Cloud
28th Jun 20227:00 amRNSIssue of Equity
15th Jun 20227:00 amRNSHalf-year Report
19th May 20227:00 amRNSFY22 H1 trading update
19th Apr 202212:36 pmRNSHolding(s) in Company
5th Apr 20227:00 amRNSDirector/PDMR Shareholding
1st Apr 20227:00 amRNSGrant of Options
28th Mar 20227:13 amRNSExercise of Share Options & Total Voting Rights
23rd Mar 20229:51 amRNSExercise of Share Options & Total Voting Rights
16th Mar 202211:22 amRNSResult of AGM & Board Change
16th Mar 20227:00 amRNSAGM Trading Update
21st Feb 20227:01 amRNSPosting of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.